Publication
RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma.
Barbara Botto, Carola Boccomini, Andrea Evangelista, Vittorio Ruggero Zilioli, Antonella Anastasia, Federica Cavallo, Francesco Merli, Manuela Zanni, Monica Tani, Annalisa Chiarenza, Anna Marina Liberati, Annarita Conconi, Chiara Rusconi, Alessia Bari, Ilaria Del Giudice, Gianluca Gaidano, Michele Spina, Nilla Maschio, Claudia Castellino, Delia Rota-Scalabrini, Benedetta Puccini, Annalisa Arcari, Sara Bigliardi, Giorgia Matta, Benedetta Bianchi, Donato Mannina, Dario Marino, Piero Galieni, Fabrizio Ciambelli, Gerardo Musuraca, Cristina Muzi, Chiara Bottelli, Elisa Genuardi, Erika Meli, Simone Ferrero, Stefano Luminari, Marco Ladetto, Giovannino Ciccone, Umberto Vitolo
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Maintenance treatment in older patients with relapsed or refractory (R/R) follicular lymphoma (FL) remains an area of investigation. RENOIR was a multicenter, phase 3, open-label randomized trial conducted by the Fondazione Italiana Linfomi (FIL) in older patients with R/R FL after 1 or 2 previous…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT02390869registry_reference1.00
Registered trialsNCT02390869
Curated evidence
Evidence citing this paper (0)
Data not yet available